The economic burden of anemia in cancer patients receiving chemotherapy.

Publication Type:

Journal Article


Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, Volume 8, Issue 2, p.149-56 (2005)


Aged, Anemia, Antineoplastic Agents, Blood Transfusion, Cost of Illness, Erythropoietin, Female, Health Expenditures, Humans, Insurance Claim Review, Male, Medicare, Medicare Part B, Neoplasms, Outcome Assessment (Health Care), Recombinant Proteins, Retrospective Studies, United States


Anemia is one of the most common hematologic complications of cancer and cytotoxic treatment. The economic burden associated with anemia in patients with malignancy has not yet been extensively studied.